AU2016411388A1 - Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease - Google Patents
Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease Download PDFInfo
- Publication number
- AU2016411388A1 AU2016411388A1 AU2016411388A AU2016411388A AU2016411388A1 AU 2016411388 A1 AU2016411388 A1 AU 2016411388A1 AU 2016411388 A AU2016411388 A AU 2016411388A AU 2016411388 A AU2016411388 A AU 2016411388A AU 2016411388 A1 AU2016411388 A1 AU 2016411388A1
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- ser
- gly
- sequence
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2016/037708 WO2017217985A1 (en) | 2016-06-15 | 2016-06-15 | Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2016411388A1 true AU2016411388A1 (en) | 2018-11-08 |
Family
ID=56292925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2016411388A Pending AU2016411388A1 (en) | 2016-06-15 | 2016-06-15 | Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3472202A1 (zh) |
JP (2) | JP2019521981A (zh) |
CN (1) | CN109311972A (zh) |
AR (1) | AR108790A1 (zh) |
AU (1) | AU2016411388A1 (zh) |
BR (1) | BR112018076287A2 (zh) |
CA (1) | CA3020894A1 (zh) |
EA (1) | EA201892707A1 (zh) |
MX (1) | MX2018015363A (zh) |
TW (2) | TW201803591A (zh) |
WO (1) | WO2017217985A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3558369A4 (en) | 2016-12-21 | 2020-09-09 | Cephalon, Inc. | ANTIBODIES SPECIFICALLY BINDING TO HUMAN IL-15 AND THEIR USES |
JP2022512709A (ja) * | 2018-10-31 | 2022-02-07 | ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー | 炎症性疾患及び自己免疫疾患を処置する組成物及び方法 |
IL310275A (en) | 2021-08-12 | 2024-03-01 | Amgen Inc | Antibody formulations |
WO2024028448A1 (en) | 2022-08-04 | 2024-02-08 | Calypso Biotech Sa | Il-15 inhibitors useful for the treatment of atopic dermatitis |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7247304B2 (en) * | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
EA015897B1 (ru) * | 2003-02-26 | 2011-12-30 | Генмаб А/С | Применение человеческого моноклонального антитела к ил-15 в составе композиции и лекарственного препарата (варианты), композиция и лекарственный препарат, его включающие |
UA102722C2 (en) * | 2009-01-29 | 2013-08-12 | Эббви Инк. | Il-1 binding proteins |
WO2011031986A1 (en) * | 2009-09-10 | 2011-03-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health | Assays for soluble il-15 receptor alpha |
EP2963057A1 (en) * | 2014-07-02 | 2016-01-06 | Calypso Biotech SA | Antibodies to IL-15 |
-
2016
- 2016-06-15 CA CA3020894A patent/CA3020894A1/en active Pending
- 2016-06-15 JP JP2018565345A patent/JP2019521981A/ja active Pending
- 2016-06-15 AU AU2016411388A patent/AU2016411388A1/en active Pending
- 2016-06-15 MX MX2018015363A patent/MX2018015363A/es unknown
- 2016-06-15 BR BR112018076287-3A patent/BR112018076287A2/pt active Search and Examination
- 2016-06-15 EP EP16733804.5A patent/EP3472202A1/en active Pending
- 2016-06-15 WO PCT/US2016/037708 patent/WO2017217985A1/en unknown
- 2016-06-15 CN CN201680086774.8A patent/CN109311972A/zh active Pending
- 2016-06-15 EA EA201892707A patent/EA201892707A1/ru unknown
-
2017
- 2017-06-15 TW TW106119998A patent/TW201803591A/zh unknown
- 2017-06-15 TW TW111144466A patent/TW202327653A/zh unknown
- 2017-06-15 AR ARP170101652A patent/AR108790A1/es unknown
-
2021
- 2021-09-24 JP JP2021155175A patent/JP2022001577A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3472202A1 (en) | 2019-04-24 |
CN109311972A (zh) | 2019-02-05 |
BR112018076287A2 (pt) | 2019-03-26 |
MX2018015363A (es) | 2019-04-15 |
JP2022001577A (ja) | 2022-01-06 |
TW202327653A (zh) | 2023-07-16 |
EA201892707A1 (ru) | 2019-05-31 |
TW201803591A (zh) | 2018-02-01 |
AR108790A1 (es) | 2018-09-26 |
WO2017217985A1 (en) | 2017-12-21 |
CA3020894A1 (en) | 2017-12-21 |
JP2019521981A (ja) | 2019-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220002428A1 (en) | Binding molecules to the human ox40 receptor | |
TWI359671B (en) | Cd40 antibody formulation and methods | |
BR112019024556A2 (pt) | Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer | |
AU2016204960A1 (en) | 4-1BB binding molecules | |
US10983128B2 (en) | CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy | |
BR112020018539A2 (pt) | Anticorpos contra mica e/ou micb e usos dos mesmos | |
JP2022101631A (ja) | 抗pd‐l1抗体とil‐7との融合 | |
JP2022001577A (ja) | セリアック病、非セリアックグルテン過敏症及び難治性セリアック病を治療するための方法及び組成物 | |
KR20210039986A (ko) | Ox40에 대한 완전한 인간 항체, 이를 준비하는 방법 및 이의 용도 | |
JP2020503860A (ja) | 免疫応答のコンディショナルアゴニスト | |
US20230312701A1 (en) | Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease | |
US20240010729A1 (en) | Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer | |
US20100119517A1 (en) | Use of Anti-MAdCAM Antibodies for the Treatment of Coeliac Disease and Tropical Sprue | |
US20240158510A1 (en) | Antibodies against integrin heterodimers and uses thereof | |
AU2018202095B2 (en) | Binding Molecules to the Human OX40 Receptor |